Metraipolis › archive › dc_608f024bb6e5

Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants… — Europe PMC PMID:41620988

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41620988
DOI: 10.1007/s11136-[numero omesso]-4
License (as archived): solo-consultazione
Archived: 2026-11-06T08:59:55.339Z
SHA-256 of the archived text: a53a87cda01e1f697053942bcb4ff3885ecfdc41c848febbadeccaec9f6126bc
Stable URL of this page: https://metraipolis.com/documento/dc_608f024bb6e5

How to cite

Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants… — Europe PMC PMID:41620988 — Europe PMC (en), https://europepmc.org/article/MED/41620988 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_608f024bb6e5 (Metraipolis archive dc_608f024bb6e5, sha256 a53a87cda01e1f697053942bcb4ff3885ecfdc41c848febbadeccaec9f6126bc)

BibTeX

@misc{dc608f024bb6e5,
  title = {Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants… — Europe PMC PMID:41620988},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41620988},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_608f024bb6e5; sha256 a53a87cda01e1f697053942bcb4ff3885ecfdc41c848febbadeccaec9f6126bc},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41620988. Agents can read the archived copy with the MCP tool read_document.